RSS   Newsletter   Contact   Advertise with us

Syndax Pharma appoints CEO and COO

Share on Twitter Share on LinkedIn
Staff writer | Waltham, Mass., USA | June 16, 2015
Syndax PharmaceuticalsJune 16, 2015, Waltham, Mass., USA - Syndax Pharmaceuticals announced that Briggs W. Morrison is joining the company as CEO and a member of the board, and Michael A. Metzger as president and COO.
As Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca from 2012 to 2015, Dr. Morrison led the company's global, late-stage development organization and served as a member of the AstraZeneca Senior Executive Team.

Prior to joining AstraZeneca, Dr. Morrison held a number of positions at Pfizer from 2007 to 2012 that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer's human health business. He previously served in roles of increasing responsibility at Merck Research Laboratories from 1995 to 2007, where he was ultimately appointed to the role of Vice President, Clinical Sciences, Oncology.

Dr. Morrison is Chairman of the Board of Transcelerate, a member of the Executive Committee of CTTI (the Clinical Trials Transformation Initiative sponsored by FDA) and is on the Board of ACRES (Alliance for Clinical Research Excellence and Safety).

Dr. Morrison received a B.S. in Biology from Georgetown University, Phi Beta Kappa, and an M.D. from the University of Connecticut, followed by an internship and residency in Internal Medicine at the MassachusettsGeneral Hospital, a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and a post-doctoral research fellowship in Genetics at Harvard Medical School.

Most recently, Mr. Metzger held the positions of President, Chief Executive Officer and a member of the Board of Directors of Regado Biosciences through the company's strategic merger with Tobira Therapeutics in 2015.

Previously, Mr. Metzger served as Executive Vice President and Chief Operating Officer at Mersana Therapeutics, a privately held biopharmaceutical company, from 2011 to 2013, and in senior Business Development positions including leading Mergers and Acquisitions at Forest Laboratories, Inc. from 2006 to 2011.

Prior to Forest, Mr. Metzger served as Vice President, Corporate Development at Onconova Therapeutics from 2001 until 2006 and was a Managing Director at Mesa Partners from 1997 to 2001.

Mr. Metzger holds a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.


 LATEST MOVES FROM Massachusetts 


MORE INSIDE POST